Julphar Gulf Pharmaceutical Industries launched the antibiotic Voxin during a launch event, which was held at the Raffles Hotel, Dubai on November 25th 2016.
“Voxin (Levofloxacin) is a fluoroquinolone antibiotic that is indicated for the treatment of lower respiratory tract infections and sinusitis in adult patients,” said Dr Hosam Badr, Director of Marketing at Julphar. “Voxin (Levofloxacin) efficacy in the respiratory tract infections is well documented in bioequivalence studies. Moreover, Voxin is very convenient for patients because of its simple once daily dose.”
Around 120 doctors and pharmacists attended the event to hear Dr Bassam Mahboub, President of the Emirates Allergy and Respiratory Society (EARS) and Prof. Tobias Welte, Head of the Pulmonary Department and Infectious Diseases at the Hannover Medical School, Germany discuss the principles of management of chest infections and give an overview of Levofloxacin as one of the best solutions for the management of such infections.
Prof. Tobias showed updated clinical trials and patient cases that ensured the benefits of Levoflixacin use in the respiratory tract infections, even in severe cases with resistant types of bacteria and how those patients got better in a shorter course of time.
Julphar’s Adult Primary Care line strives to provide patients and healthcare professionals (HCPs) with a full range of high quality antibiotics to treat infectious diseases, and serves the Julphar mission of improving patients’ quality of life.
Established in 1980, Julphar is the largest generic pharmaceutical manufacturer in Middle East and North Africa, producing over 200 branded products across its fifteen manufacturing facilities. Julphar’s mission is to offer high quality medicines at affordable prices, and its product portfolio includes: Wound, Anemia and Women Care, Adult Primary Care, Pediatric Primary Care, Gastro Care and Pain Management, Cardiopulmonary Care, and Consumer Care. In 2012 Julphar launched Julphar Diabetes, a 150 million-dollar Active Pharmaceutical Ingredient (API) manufacturing facility that has the capacity to produce 1,500 kg of recombinant human insulin and insulin analogues crystals (rDNA). Julphar employs approximately 3,000 people around the world and registered sales revenue of AED 1.47 billion in the year ending 2015. For more information, please visit http://www.julphar.net.
Marketing Director, +971 72461661